NR1H4 and metabolic dysfunction-associated steatotic liver disease: Typical examples being the peroxisome proliferator-activated receptors and the farnesoid X receptor for which ongoing clinical trials are determining efficacy in non-alcoholic fatty liver disease (NAFLD) and autoimmune liver disease [1], [2], [3].